Nerviano Medical Sciences
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nerviano Medical Sciences
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.
- Other Names / Subsidiaries
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.